A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.

We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pronzato, P., Bertelli, G., Vigani, A., Vaira, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074481/
https://www.ncbi.nlm.nih.gov/pubmed/8645591
_version_ 1782137975997464576
author Pronzato, P.
Bertelli, G.
Vigani, A.
Vaira, F.
author_facet Pronzato, P.
Bertelli, G.
Vigani, A.
Vaira, F.
author_sort Pronzato, P.
collection PubMed
description We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these, 13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical complete response was observed in 9 out of 16 evaluable patients (56.2%).
format Text
id pubmed-2074481
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20744812009-09-10 A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Pronzato, P. Bertelli, G. Vigani, A. Vaira, F. Br J Cancer Research Article We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22 patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these, 13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical complete response was observed in 9 out of 16 evaluable patients (56.2%). Nature Publishing Group 1996-06 /pmc/articles/PMC2074481/ /pubmed/8645591 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Pronzato, P.
Bertelli, G.
Vigani, A.
Vaira, F.
A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
title A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
title_full A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
title_fullStr A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
title_full_unstemmed A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
title_short A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer.
title_sort feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (pec) in advanced ovarian cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074481/
https://www.ncbi.nlm.nih.gov/pubmed/8645591
work_keys_str_mv AT pronzatop afeasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT bertellig afeasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT vigania afeasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT vairaf afeasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT pronzatop feasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT bertellig feasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT vigania feasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer
AT vairaf feasibilitystudyofacceleratedpolychemotherapywithcisplatinepidoxorubicinandcyclophosphamidepecinadvancedovariancancer

Ejemplares similares